Is Peginterferon Alpha-2a More Effective Than Lamivudine for Hepatitis B?

Is interferon better than Hepatitis B immunoglobulin?

Hello, I am a 25-year-old patient with hepatitis B who contracted the virus through vertical transmission from my mother and is e-antigen positive.
I have been taking lamivudine for nearly a year, but I still have not achieved e-antigen seroconversion.
My doctor has suggested interferon injection therapy, stating that one-third of his patients experience e-antigen seroconversion with this treatment, which is higher than the likelihood of seroconversion with lamivudine.
I would like to inquire if the National Health Insurance covers Peginterferon alpha-2a.
Is this long-acting interferon (PEGASYS) superior to interferon-alpha? Additionally, would you recommend that I pursue interferon injection therapy? Thank you.

alpha, 20~29 year old female. Ask Date: 2005/04/06

Dr. Xu Jinchuan reply Gastroenterology and Hepatology

Hello! The National Health Insurance does not cover long-acting interferons, only short-acting interferons are covered.
According to the data, long-acting interferons are more effective than short-acting ones.
Based on experience, some patients may only show seroconversion of the e antigen in later stages, so it is not always necessary to initiate interferon treatment immediately; observation can also be an option.

Reply Date: 2005/04/06

More Info

When considering the treatment options for chronic Hepatitis B, particularly in patients who are HBeAg positive, the choice between Peginterferon Alpha-2a and Lamivudine is significant. Both medications have their roles in managing the disease, but they operate through different mechanisms and have varying efficacy rates.

Lamivudine is a nucleoside analogue that inhibits the reverse transcriptase enzyme of the Hepatitis B virus (HBV). It has been widely used due to its oral administration and relatively favorable side effect profile. However, one of the major drawbacks of Lamivudine is the potential for developing drug resistance. Studies have shown that after one year of treatment, a significant percentage of patients may develop resistance, leading to an increase in HBV DNA levels and liver enzyme elevations. This resistance can limit the long-term effectiveness of Lamivudine, necessitating the addition of other antiviral agents, such as Adefovir or Tenofovir, to manage the infection effectively.

On the other hand, Peginterferon Alpha-2a is an injectable medication that enhances the immune response against HBV. It has been shown to induce a higher rate of HBeAg seroconversion compared to Lamivudine, particularly in patients who are HBeAg positive. The seroconversion rate, which refers to the transition from positive to negative HBeAg status, is a crucial marker of treatment success. Clinical studies indicate that approximately 30% of patients treated with Peginterferon Alpha-2a achieve this outcome, which is significantly higher than the rates observed with Lamivudine alone.

In terms of side effects, Peginterferon can cause flu-like symptoms, fatigue, and hematological changes, which may lead to discontinuation in some patients. However, its ability to promote a sustained immune response makes it a valuable option, especially for younger patients or those with a higher likelihood of achieving seroconversion.

Regarding the question of whether Peginterferon Alpha-2a is more effective than Lamivudine, the evidence suggests that Peginterferon has a superior efficacy profile in terms of achieving HBeAg seroconversion and potentially leading to a functional cure. However, the choice of treatment should also consider patient preferences, potential side effects, and the likelihood of adherence to an injectable regimen.

In Taiwan, the National Health Insurance may cover Peginterferon Alpha-2a under specific conditions, but it is essential to consult with a healthcare provider to understand the eligibility criteria and whether it is the most appropriate option for your situation.
In conclusion, while Lamivudine is a valuable treatment option for chronic Hepatitis B, Peginterferon Alpha-2a may offer better outcomes in terms of HBeAg seroconversion. It is advisable to discuss with your healthcare provider the potential benefits and risks of switching to Peginterferon, considering your current treatment response and overall health status. Regular monitoring and follow-up are crucial in managing chronic Hepatitis B effectively, regardless of the chosen treatment.

Similar Q&A

Effectiveness of Lamivudine and Interferon for Treating Hepatitis B Patients

I would like to ask whether medications like lamivudine and interferon are effective for patients with hepatitis B. I saw online that lamivudine was originally used to treat HIV, but later it was noted that HIV patients with co-infection of hepatitis B experienced a decrease in h...

Dr. Chen Zhiping reply Gastroenterology and Hepatology
Hello, these two medications are currently used for the treatment of chronic hepatitis B. For patients with long-term abnormal liver function tests, Lanivudine (also known as Lamivudine) can be administered orally, or interferon can be given via injection, depending on the situat...

Effective Treatments for Hepatitis B: Vaccines and Immunoglobulin Use

Hello, doctor. What is the treatment for hepatitis B? Also, if someone already has hepatitis B, can they receive the hepatitis B vaccine and immunoglobulin to improve their condition? Thank you for your response.

Dr. Liang Jiade reply Gastroenterology and Hepatology
Hello, if you have hepatitis B, you need to be tested to determine if there is active hepatitis before deciding on medication treatment. Currently, the available treatment options in the country include Lamivudine, Adefovir, and interferon injection therapy. As for whether treatm...

Choosing the Best Treatment for Chronic Hepatitis B: Interferon vs. New Oral Antivirals

Hello: I have been undergoing treatment for hepatitis B for over three years. Initially, I was treated with interferon, and there was a period when my AST and ALT levels dropped to normal (although the e-antigen remained positive, and the viral load decreased from 1950 to 38). Af...

Dr. Xu Jinchuan reply Gastroenterology and Hepatology
Hello! Recently, your GPT index has increased. Besides Danazol, long-acting interferons are also one of the treatment options. However, they are currently not covered by health insurance and must be paid for out-of-pocket. The efficacy of both treatments is quite similar, but for...

Understanding Hepatitis B Mutations and Their Treatment Challenges

Hello Doctor: In early February, I felt unwell and went to the hospital for liver function tests. There was no infection with hepatitis B or C. The results showed liver enzyme levels of GOT 66 and GPT 108, while other liver function tests and ultrasound were normal, except for a ...

Dr. Chen Zhiping reply Gastroenterology and Hepatology
Reply: Hello, initially it was stated that there was no hepatitis B or C, but later it was mentioned that HBV-DNA is positive and it is a mutant strain of the virus. However, shouldn't the hepatitis B surface antigen be positive? I have not encountered such a situation perso...